What is dihexa?

• What dihexa is and how it descends from angiotensin IV
• The proposed HGF/c-Met mechanism, framed as a hypothesis not a fact
• Why the two most-cited dihexa papers were retracted or flagged
• How the fosgonimeton trials and the c-Met oncology signal reframe the hype

1. 01 What is dihexa? A cognitive peptide with huge animal claims and no human data free
2. 02 Chemistry & structure How dihexa is built from angiotensin IV paid
3. 03 The HGF/c-Met hypothesis The proposed mechanism, and why it is a hypothesis paid
4. 04 The preclinical evidence What the animal and cell studies actually show paid
5. 05 The research-integrity problem The retraction and the expression of concern paid
6. 06 The fosgonimeton translation The successor compound that reached humans, and failed paid
7. 07 Dosing & Administration What the community reports, and why no dose is established paid
8. 08 Safety & Side Effects The c-Met oncology signal and the missing safety data paid
9. 09 Regulatory context Not approved, and in regulatory limbo paid
10. 10 Final Exam & Certification Pass the final exam to earn your specialist certificate. exam

Dihexa was not discovered by accident. It is the end point of a decades-long program in the Harding and Wright lab at Washington State University, which studied how a fragment of the blood-pressure hormone system could sharpen memory in rats. Each generation of molecule was trimmed and stabilized to survive longer in the body.

Notice how the marketing-friendly story arrived late and then partly collapsed. The clean, early work is about angiotensin IV analogs and spines; the bold HGF/c-Met headline came in 2014 and was retracted in 2025.

Despite being called a "hexapeptide" in vendor copy, dihexa is chemically a two-residue core (tyrosine and isoleucine) wearing two fatty caps. Those caps are the engineering trick that lets it survive in the body long enough to reach the brain.

The "di" plus "hexa" in the name refers to two six-carbon (hexanoic) appendages, not to six amino acids. That single naming point is where most misunderstandings of dihexa begin, so it is worth fixing early.

Search dihexa and you will meet confident superlatives: "reverses Alzheimer's", "regrows neurons", "ten million times stronger than BDNF". Each is either an overreach or a misread of a single cell-culture measurement. The useful skill is holding each claim against its actual evidence.

Most of these claims are not simply false. They are real laboratory observations that have been rounded up into human promises they cannot support. Learning to see that gap is what this course trains.

Before any mechanism detail, here is the honest ceiling: what is genuinely supported for dihexa, and what is merely hoped for. The distance between the top and bottom rows of this table is the entire point of the course. Read down the tiers and notice how quickly the evidence thins, from a real but narrow animal signal at the top to a complete absence of human data at the bottom.

A gauge this low is unusual for a compound with so much online enthusiasm, and that mismatch is the story. The score is not a verdict that dihexa does nothing; it is a measure of how little we can actually claim to know about it in people.

The "ten million times stronger than BDNF" line is the most-repeated dihexa claim, so it deserves a careful look. It compares how low a concentration triggered spine growth in a dish, not how well either molecule treats a human brain.

A drug can be extraordinarily potent and still completely fail, because potency is a laboratory concentration and efficacy is a clinical result. Conflating the two is the single most common error in dihexa marketing.

The rest of the course walks the evidence in order: the chemistry, the proposed mechanism, the preclinical data, the integrity actions, the failed successor trials, the dosing and safety picture, and the regulatory limbo. Each unit keeps the same honest posture.

By the end you should be able to state cleanly what is established, what is hypothesized, and what is simply unknown about dihexa, and to spot the claims that blur those lines.